Portfolio Companies
Co-founded by EMBLEM since 1999
We invest in core technologies that can be developed into successful, profitable businesses over time. The EMBL technology portfolio has generated more than 20 companies co-founded by EMBLEM since 1999 and new promising technologies continue to be established.
EMBLEM’s experience in founding new companies and our close working relationship EMBL’s collaboration partners in various industries provide the ideal environment for young start-ups. Please find a selection of our spin-off companies below.
Epitome Therapeutics
Epitome Therapeutics is a Vienna-based, next-generation epigenetic editing company spun out from EMBL in 2025. The company is developing CADENCE, a programmable platform for precise and durable activation of endogenous…
Umlaut.bio
Umlaut.bio is a preclinical biotech-company targeting the modification of tRNAs for the therapy of cancer and autoimmune diseases. Umlaut.bio GmbH develops first-in-biology small molecules focusing on the “umlauts” of the…
DenovAI Biotech
Founded in 2023 by former EMBL scientist Kashif Sadiq, DenovAI Biotech operates at the nexus of artificial intelligence and computational biophysics. DenovAI’s mission is to provide a transformative solution for…
Borea Therapeutics
Borea Therapeutics is an innovative biotech start-up located in Milan, and co-founded by Professor Paul Heppenstall and EMBLEM, the technology transfer partner of EMBL (European Molecular Biology Laboratory), and backed…